

Stephen Finn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6524694/publications.pdf>

Version: 2024-02-01

154
papers

7,827
citations

53660

45
h-index

58464

82
g-index

160
all docs

160
docs citations

160
times ranked

14304
citing authors

#	ARTICLE	IF	CITATIONS
1	Cancer Immunotherapy with Immune Checkpoint Inhibitors-Biomarkers of Response and Toxicity; Current Limitations and Future Promise. <i>Diagnostics</i> , 2022, 12, 124.	1.3	12
2	Inflammation and Prostate Cancer: A Multidisciplinary Approach to Identifying Opportunities for Treatment and Prevention. <i>Cancers</i> , 2022, 14, 1367.	1.7	10
3	Radium-223 in combination with enzalutamide in metastatic castration-resistant prostate cancer: a multi-centre, phase II open-label study. <i>Therapeutic Advances in Medical Oncology</i> , 2021, 13, 175883592110426.	1.4	8
4	Correlation of integrated ERG/PTEN assessment with biochemical recurrence in prostate cancer. <i>Cancer Treatment and Research Communications</i> , 2021, 29, 100451.	0.7	4
5	Feature fusion of Raman chemical imaging and digital histopathology using machine learning for prostate cancer detection. <i>Analyst</i> , 2021, 146, 4195-4211.	1.7	11
6	Differential CircRNA Expression Signatures May Serve as Potential Novel Biomarkers in Prostate Cancer. <i>Frontiers in Cell and Developmental Biology</i> , 2021, 9, 605686.	1.8	11
7	Diagnostic Strategies for Treatment Selection in Advanced Prostate Cancer. <i>Diagnostics</i> , 2021, 11, 345.	1.3	14
8	Association of Prediagnostic Blood Metabolomics with Prostate Cancer Defined by ERG or PTEN Molecular Subtypes. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 1000-1008.	1.1	2
9	Molecular Subtyping of Diffuse Large B-Cell Lymphoma Using a Novel Quantitative RT-PCR Assay. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 323-340.	1.2	2
10	Development of EphA2 siRNA-loaded lipid nanoparticles and combination with a small molecule histone demethylase inhibitor in prostate cancer cells and tumor spheroids. <i>Journal of Nanobiotechnology</i> , 2021, 19, 71.	4.2	24
11	Co-Targeting PIM Kinase and PI3K/mTOR in NSCLC. <i>Cancers</i> , 2021, 13, 2139.	1.7	6
12	Exploitation of the vitamin A/retinoic acid axis depletes ALDH1-positive cancer stem cells and re-sensitises resistant non-small cell lung cancer cells to cisplatin. <i>Translational Oncology</i> , 2021, 14, 101025.	1.7	12
13	MicroRNA expression profiling and biomarker validation in treatment-naïve and drug resistant non-small cell lung cancer. <i>Translational Lung Cancer Research</i> , 2021, 10, 1773-1791.	1.3	7
14	RET Fluorescence In Situ Hybridization Analysis Is a Sensitive but Highly Unspecific Screening Method for RET Fusions in Lung Cancer. <i>Journal of Thoracic Oncology</i> , 2021, 16, 798-806.	0.5	28
15	Prognostic Impact of KRAS G12C Mutation in Patients With NSCLC: Results From the European Thoracic Oncology Platform Lungscape Project. <i>Journal of Thoracic Oncology</i> , 2021, 16, 990-1002.	0.5	37
16	Deep Learning of Histopathological Features for the Prediction of Tumour Molecular Genetics. <i>Diagnostics</i> , 2021, 11, 1406.	1.3	15
17	The Liquid Biopsy for Lung Cancer: State of the Art, Limitations and Future Developments. <i>Cancers</i> , 2021, 13, 3923.	1.7	33
18	Longitudinal analysis of individual cfDNA methylome patterns in metastatic prostate cancer. <i>Clinical Epigenetics</i> , 2021, 13, 168.	1.8	14

#	ARTICLE	IF	CITATIONS
19	Circulating Tumour Cell Numbers Correlate with Platelet Count and Circulating Lymphocyte Subsets in Men with Advanced Prostate Cancer: Data from the ExPeCT Clinical Trial (CTRIAL-IE 15-21). <i>Cancers</i> , 2021, 13, 4690.	1.7	11
20	Gene Expression Pathways in Prostate Tissue Associated with Vigorous Physical Activity in Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2021, 30, 751-756.	1.1	1
21	Pathogenic BRCA Variants as Biomarkers for Risk in Prostate Cancer. <i>Cancers</i> , 2021, 13, 5697.	1.7	10
22	hsa_circ_0001275 Is One of a Number of circRNAs Dysregulated in Enzalutamide Resistant Prostate Cancer and Confers Enzalutamide Resistance In Vitro. <i>Cancers</i> , 2021, 13, 6383.	1.7	3
23	Family history of prostate cancer and the incidence of ERG and phosphatase and tensin homolog defined prostate cancer. <i>International Journal of Cancer</i> , 2020, 146, 2694-2702.	2.3	3
24	Programmed death-ligand 1 expression influenced by tissue sample size. Scoring based on tissue microarrays and cross-validation with resections, in patients with, stage III, non-small cell lung carcinoma of the European Thoracic Oncology Platform Lungscape cohort. <i>Modern Pathology</i> , 2020, 33, 792-801.	2.9	28
25	Current perspectives on targeting PIM kinases to overcome mechanisms of drug resistance and immune evasion in cancer. , 2020, 207, 107454.		21
26	Statin Use Is Associated with Lower Risk of PTEN-Null and Lethal Prostate Cancer. <i>Clinical Cancer Research</i> , 2020, 26, 1086-1093.	3.2	35
27	Prostate cancer-derived holoclones: a novel and effective model for evaluating cancer stemness. <i>Scientific Reports</i> , 2020, 10, 11329.	1.6	10
28	Tumor protein expression of the DNA repair gene BRCA1 and lethal prostate cancer. <i>Carcinogenesis</i> , 2020, 41, 904-908.	1.3	1
29	Evaluating liquid biopsies for methylomic profiling of prostate cancer. <i>Epigenetics</i> , 2020, 15, 715-727.	1.3	13
30	Platelet cloaking of circulating tumour cells in patients with metastatic prostate cancer: Results from ExPeCT, a randomised controlled trial. <i>PLoS ONE</i> , 2020, 15, e0243928.	1.1	13
31	Targeting NF- κ B-mediated inflammatory pathways in cisplatin-resistant NSCLC. <i>Lung Cancer</i> , 2019, 135, 217-227.	0.9	25
32	Circular RNAs are differentially expressed in prostate cancer and are potentially associated with resistance to enzalutamide. <i>Scientific Reports</i> , 2019, 9, 10739.	1.6	69
33	A retrospective cohort study of PD-L1 prevalence, molecular associations and clinical outcomes in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape Project. <i>Lung Cancer</i> , 2019, 131, 95-103.	0.9	40
34	When RON MET TAM in Mesothelioma: All Druggable for One, and One Drug for All?. <i>Frontiers in Endocrinology</i> , 2019, 10, 89.	1.5	10
35	Cost-Efficient and Easy to Perform PCR-Based Assay to Identify Met Exon 14 Skipping in Formalin-Fixed Paraffin-Embedded (FFPE) Non-Small Cell Lung Cancer (NSCLC) Samples. <i>Diagnostics</i> , 2019, 9, 13.	1.3	10
36	ALK immunohistochemistry positive, FISH negative NSCLC is infrequent, but associated with impaired survival following treatment with crizotinib. <i>Lung Cancer</i> , 2019, 138, 13-18.	0.9	8

#	ARTICLE	IF	CITATIONS
37	Multiplex profiling identifies clinically relevant signalling proteins in an isogenic prostate cancer model of radioresistance. <i>Scientific Reports</i> , 2019, 9, 17325.	1.6	8
38	A Prospective Study of the Association between Physical Activity and Risk of Prostate Cancer Defined by Clinical Features and TMPRSS2:ERG. <i>European Urology</i> , 2019, 76, 33-40.	0.9	26
39	BBI608 inhibits cancer stemness and reverses cisplatin resistance in NSCLC. <i>Cancer Letters</i> , 2018, 428, 117-126.	3.2	69
40	Carcinogenesis in prostate cancer: The role of long non-coding RNAs. <i>Non-coding RNA Research</i> , 2018, 3, 29-38.	2.4	33
41	Development and characterisation of a panel of phosphatidylinositide 3-kinase “ mammalian target of rapamycin inhibitor resistant lung cancer cell lines. <i>Scientific Reports</i> , 2018, 8, 1652.	1.6	9
42	Evaluation of NGS and RT-PCR Methods for ALK Rearrangement in European NSCLC Patients: Results from the European Thoracic Oncology Platform Lungscope Project. <i>Journal of Thoracic Oncology</i> , 2018, 13, 413-425.	0.5	66
43	Prevalence and clinical association of gene mutations through multiplex mutation testing in patients with NSCLC: results from the ETOP Lungscope Project. <i>Annals of Oncology</i> , 2018, 29, 200-208.	0.6	25
44	Genetic Susceptibility. <i>Molecular Pathology Library</i> , 2018, , 57-78.	0.1	0
45	Computer-Based Intensity Measurement Assists Pathologists in Scoring Phosphatase and Tensin Homolog Immunohistochemistry “ Clinical Associations in NSCLC Patients of the European Thoracic Oncology Platform Lungscope Cohort. <i>Journal of Thoracic Oncology</i> , 2018, 13, 1851-1863.	0.5	6
46	RNAs as Candidate Diagnostic and Prognostic Markers of Prostate Cancer“From Cell Line Models to Liquid Biopsies. <i>Diagnostics</i> , 2018, 8, 60.	1.3	15
47	Intense Exercise for Survival among Men with Metastatic Castrate-Resistant Prostate Cancer (INTERVAL-GAP4): a multicentre, randomised, controlled phase III study protocol. <i>BMJ Open</i> , 2018, 8, e022899.	0.8	85
48	Integrating biomarkers across omic platforms: an approach to improve stratification of patients with indolent and aggressive prostate cancer. <i>Molecular Oncology</i> , 2018, 12, 1513-1525.	2.1	41
49	Expression of IGF/insulin receptor in prostate cancer tissue and progression to lethal disease. <i>Carcinogenesis</i> , 2018, 39, 1431-1437.	1.3	35
50	A Prospective Study of Aspirin Use and Prostate Cancer Risk by <i>TMPRSS2:ERG</i> Status. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2018, 27, 1231-1233.	1.1	2
51	Pathology-Driven Comprehensive Proteomic Profiling of the Prostate Cancer Tumor Microenvironment. <i>Molecular Cancer Research</i> , 2017, 15, 281-293.	1.5	16
52	Perineural Invasion and Risk of Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2017, 26, 719-726.	1.1	51
53	Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma. <i>International Journal of Oncology</i> , 2017, 50, 1044-1052.	1.4	12
54	Deoxycholic acid promotes development of gastroesophageal reflux disease and Barrett's oesophagus by modulating integrin“+ trafficking. <i>Journal of Cellular and Molecular Medicine</i> , 2017, 21, 3612-3625.	1.6	13

#	ARTICLE	IF	CITATIONS
55	The Notch-3 receptor: A molecular switch to tumorigenesis?. <i>Cancer Treatment Reviews</i> , 2017, 60, 69-76.	3.4	10
56	Stromal and epithelial transcriptional map of initiation progression and metastatic potential of human prostate cancer. <i>Nature Communications</i> , 2017, 8, 420.	5.8	91
57	Investigating the role of the IGF axis as a predictor of biochemical recurrence in prostate cancer patients post-surgery. <i>Prostate</i> , 2017, 77, 1288-1300.	1.2	15
58	Prevalence and clinical association of MET gene overexpression and amplification in patients with NSCLC: Results from the European Thoracic Oncology Platform (ETOP) Lungscape project. <i>Lung Cancer</i> , 2017, 111, 143-149.	0.9	57
59	Gene expression profiling of prostate tissue identifies chromatin regulation as a potential link between obesity and lethal prostate cancer. <i>Cancer</i> , 2017, 123, 4130-4138.	2.0	11
60	Extraction and Quantification of Sinapinic Acid from Irish Rapeseed Meal and Assessment of Angiotensin-I Converting Enzyme (ACE-I) Inhibitory Activity. <i>Journal of Agricultural and Food Chemistry</i> , 2017, 65, 6886-6892.	2.4	16
61	The ExPeCT (Examining Exercise, Prostate Cancer and Circulating Tumour Cells) trial: study protocol for a randomised controlled trial. <i>Trials</i> , 2017, 18, 456.	0.7	6
62	Long Non-Coding RNAs: Key Regulators of Epithelial-Mesenchymal Transition, Tumour Drug Resistance and Cancer Stem Cells. <i>Cancers</i> , 2017, 9, 38.	1.7	143
63	Circular RNAs: Biogenesis, Function and Role in Human Diseases. <i>Frontiers in Molecular Biosciences</i> , 2017, 4, 38.	1.6	449
64	Targeting the cancer stem cell marker, aldehyde dehydrogenase 1, to circumvent cisplatin resistance in NSCLC. <i>Oncotarget</i> , 2017, 8, 72544-72563.	0.8	60
65	Can a biobank network and supporting infrastructure enhance Ireland's ability to attract pharmaceutical research and development and clinical trial opportunities? A pilot survey. <i>Journal of Biorepository Science for Applied Medicine</i> , 2016, , 1.	0.2	1
66	In pursuit of synergy: An investigation of the PI3K/mTOR/MEK co-targeted inhibition strategy in NSCLC. <i>Oncotarget</i> , 2016, 7, 79526-79543.	0.8	23
67	The Role of Proteomics in Biomarker Development for Improved Patient Diagnosis and Clinical Decision Making in Prostate Cancer. <i>Diagnostics</i> , 2016, 6, 27.	1.3	15
68	Exercise and Prostate Cancer: Evidence and Proposed Mechanisms for Disease Modification. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2016, 25, 1281-1288.	1.1	22
69	Targeting the fibroblast growth factor receptor family in cancer. <i>Cancer Treatment Reviews</i> , 2016, 46, 51-62.	3.4	99
70	PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered?. <i>Journal of Thoracic Oncology</i> , 2016, 11, e142-e144.	0.5	3
71	Sniffing out significant p values genome wide association study of asparagus anosmia. <i>BMJ</i> , The, 2016, 355, i6071.	3.0	11
72	Calcium-Sensing Receptor Tumor Expression and Lethal Prostate Cancer Progression. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2016, 101, 2520-2527.	1.8	30

#	ARTICLE	IF	CITATIONS
73	The IL-17-Th1/Th17 pathway: an attractive target for lung cancer therapy?. <i>Expert Opinion on Therapeutic Targets</i> , 2016, 20, 1339-1356.	1.5	28
74	Lung cancer stem cells: The root of resistance. <i>Cancer Letters</i> , 2016, 372, 147-156.	3.2	130
75	KAT5 (Tip60) is a potential therapeutic target in malignant pleural mesothelioma. <i>International Journal of Oncology</i> , 2016, 48, 1290-1296.	1.4	30
76	Dietary lycopene intake and risk of prostate cancer defined by ERG protein expression. <i>American Journal of Clinical Nutrition</i> , 2016, 103, 851-860.	2.2	65
77	Profiling the tumor microenvironment proteome in prostate cancer using laser capture microdissection coupled to LC-MS/MS technical report. <i>EuPA Open Proteomics</i> , 2016, 10, 19-23.	2.5	12
78	Cancer stem cells in drug resistant lung cancer: Targeting cell surface markers and signaling pathways. , 2016, 158, 71-90.		166
79	Diffuse oesophageal leiomyomatosis. <i>ANZ Journal of Surgery</i> , 2015, 85, 685-686.	0.3	2
80	High-throughput oncogene mutation profiling shows demographic differences in BRAF mutation rates among melanoma patients. <i>Melanoma Research</i> , 2015, 25, 189-199.	0.6	13
81	A Prospective Investigation of PTEN Loss and ERG Expression in Lethal Prostate Cancer. <i>Journal of the National Cancer Institute</i> , 2015, 108, djv346.	3.0	149
82	Optimising translational oncology in clinical practice: Strategies to accelerate progress in drug development. <i>Cancer Treatment Reviews</i> , 2015, 41, 129-135.	3.4	14
83	The emerging role of microRNAs in resistance to lung cancer treatments. <i>Cancer Treatment Reviews</i> , 2015, 41, 160-169.	3.4	83
84	Enzalutamide for treatment of CRPC: Rationale for sequencing and potential clinical biomarker for resistance. <i>Cancer Biology and Therapy</i> , 2015, 16, 201-203.	1.5	0
85	Tumor expression of adiponectin receptor 2 and lethal prostate cancer. <i>Carcinogenesis</i> , 2015, 36, 639-647.	1.3	25
86	Golgi phosphoprotein 2 (GOLPH2) is a novel bile acid-responsive modulator of oesophageal cell migration and invasion. <i>British Journal of Cancer</i> , 2015, 113, 1332-1342.	2.9	13
87	Measuring PI3K Activation: Clinicopathologic, Immunohistochemical, and RNA Expression Analysis in Prostate Cancer. <i>Molecular Cancer Research</i> , 2015, 13, 1431-1440.	1.5	15
88	Non-coding RNA repertoires in malignant pleural mesothelioma. <i>Lung Cancer</i> , 2015, 90, 417-426.	0.9	16
89	The MyD88+ Phenotype Is an Adverse Prognostic Factor in Epithelial Ovarian Cancer. <i>PLoS ONE</i> , 2014, 9, e100816.	1.1	36
90	Application of statistical process control to qualitative molecular diagnostic assays. <i>Frontiers in Molecular Biosciences</i> , 2014, 1, 18.	1.6	0

#	ARTICLE	IF	CITATIONS
91	Identification of potential therapeutic molecular targets preferentially expressed by esophageal cancer cells. <i>Expert Review of Anticancer Therapy</i> , 2014, 14, 267-269.	1.1	1
92	Strategic targeting of the PI3K-RAF axis in cisplatin-resistant NSCLC. <i>Cancer Biology and Therapy</i> , 2014, 15, 1367-1377.	1.5	23
93	Kidney Volume Correlates With Tumor Diameter in Renal Cell Carcinoma and Is Associated With Histological Poor Prognostic Features. <i>International Journal of Surgical Pathology</i> , 2014, 22, 39-46.	0.4	2
94	Predictive Values for Molecular Diagnostics: Converting Unknown Unknowns to Known Unknowns. <i>Molecular Diagnosis and Therapy</i> , 2014, 18, 1-4.	1.6	2
95	SPINK1 Protein Expression and Prostate Cancer Progression. <i>Clinical Cancer Research</i> , 2014, 20, 4904-4911.	3.2	71
96	The role of DNA repair pathways in cisplatin resistant lung cancer. <i>Cancer Treatment Reviews</i> , 2014, 40, 1161-1170.	3.4	114
97	Molecular testing in oncology: Problems, pitfalls and progress. <i>Lung Cancer</i> , 2014, 83, 309-315.	0.9	23
98	Optimal management of metastatic castration-resistant prostate cancer: Highlights from a European Expert Consensus Panel. <i>European Journal of Cancer</i> , 2014, 50, 1617-1627.	1.3	133
99	DNA Repair Biomarkers XPF and Phospho-MAPKAP Kinase 2 Correlate with Clinical Outcome in Advanced Head and Neck Cancer. <i>PLoS ONE</i> , 2014, 9, e102112.	1.1	14
100	Prostate-Specific Membrane Antigen Protein Expression in Tumor Tissue and Risk of Lethal Prostate Cancer. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 2354-2363.	1.1	99
101	Protein Expression of PTEN, Insulin-Like Growth Factor I Receptor (IGF-IR), and Lethal Prostate Cancer: A Prospective Study. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2013, 22, 1984-1993.	1.1	41
102	Modification of the Association Between Obesity and Lethal Prostate Cancer by TMPRSS2:ERG. <i>Journal of the National Cancer Institute</i> , 2013, 105, 1881-1890.	3.0	80
103	Pre-Treatment of Platinum Resistant Ovarian Cancer Cells with an MMP-9/MMP-2 Inhibitor Prior to Cisplatin Enhances Cytotoxicity as Determined by High Content Screening. <i>International Journal of Molecular Sciences</i> , 2013, 14, 2085-2103.	1.8	23
104	Gleason Grade Progression Is Uncommon. <i>Cancer Research</i> , 2013, 73, 5163-5168.	0.4	76
105	Development and Progress of Ireland's Biobank Network: Ethical, Legal, and Social Implications (ELSI), Standardized Documentation, Sample and Data Release, and International Perspective. <i>Biopreservation and Biobanking</i> , 2013, 11, 3-11.	0.5	19
106	Utility of multispectral imaging in automated quantitative scoring of immunohistochemistry. <i>Journal of Clinical Pathology</i> , 2012, 65, 496-502.	1.0	56
107	IGF-1 and Its Receptor in Esophageal Cancer: Association with Adenocarcinoma and Visceral Obesity. <i>American Journal of Gastroenterology</i> , 2012, 107, 196-204.	0.2	96
108	RET protein expression in papillary renal cell carcinoma. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2012, 30, 900-905.	0.8	14

#	ARTICLE	IF	CITATIONS
109	Platelet Adhesion and Degranulation Induce Pro-Survival and Pro-Angiogenic Signalling in Ovarian Cancer Cells. PLoS ONE, 2011, 6, e26125.	1.1	141
110	Common Polymorphisms in the Adiponectin and Its Receptor Genes, Adiponectin Levels and the Risk of Prostate Cancer. Cancer Epidemiology Biomarkers and Prevention, 2011, 20, 2618-2627.	1.1	50
111	mRNA Expression Signature of Gleason Grade Predicts Lethal Prostate Cancer. Journal of Clinical Oncology, 2011, 29, 2391-2396.	0.8	140
112	Immunohistochemical Expression of BRCA1 and Lethal Prostate Cancer. Cancer Research, 2010, 70, 3136-3139.	0.4	110
113	Fatty Acid Synthase Polymorphisms, Tumor Expression, Body Mass Index, Prostate Cancer Risk, and Survival. Journal of Clinical Oncology, 2010, 28, 3958-3964.	0.8	113
114	Genetic variation in RNASEL associated with prostate cancer risk and progression. Carcinogenesis, 2010, 31, 1597-1603.	1.3	54
115	B-Raf ^{V600E} and thrombospondin-1 promote thyroid cancer progression. Proceedings of the National Academy of Sciences of the United States of America, 2010, 107, 10649-10654.	3.3	164
116	Systems-Level Modeling of Cancer-Fibroblast Interaction. PLoS ONE, 2009, 4, e6888.	1.1	23
117	Fatty Acid Synthase: A Metabolic Enzyme and Candidate Oncogene in Prostate Cancer. Journal of the National Cancer Institute, 2009, 101, 519-532.	3.0	328
118	RET/PTC Rearrangement Occurring in Primary Peritoneal Carcinoma. International Journal of Surgical Pathology, 2009, 17, 187-197.	0.4	15
119	FOXA1 Is a Potential Oncogene in Anaplastic Thyroid Carcinoma. Clinical Cancer Research, 2009, 15, 3680-3689.	3.2	75
120	Gleason Score and Lethal Prostate Cancer: Does 3 + 4 = 4 + 3?. Journal of Clinical Oncology, 2009, 27, 3459-3464.	0.8	329
121	Potentially important microRNA cluster on chromosome 17p13.1 in primary peritoneal carcinoma. Modern Pathology, 2009, 22, 197-205.	2.9	80
122	Bead-based profiling of tyrosine kinase phosphorylation identifies SRC as a potential target for glioblastoma therapy. Nature Biotechnology, 2009, 27, 77-83.	9.4	210
123	miR-29b Expression Is Associated With Disease-Free Survival in Patients With Ovarian Serous Carcinoma. International Journal of Gynecological Cancer, 2009, 19, 641-647.	1.2	55
124	Endothelial NOS, estrogen receptor β , and HIFs cooperate in the activation of a prognostic transcriptional pattern in aggressive human prostate cancer. Journal of Clinical Investigation, 2009, 119, 1093-1108.	3.9	110
125	Overexpression of fatty acid synthase is associated with palmitoylation of Wnt1 and cytoplasmic stabilization of β -catenin in prostate cancer. Laboratory Investigation, 2008, 88, 1340-1348.	1.7	116
126	Altered eIF6 and Dicer expression is associated with clinicopathological features in ovarian serous carcinoma patients. Modern Pathology, 2008, 21, 676-684.	2.9	91

#	ARTICLE	IF	CITATIONS
127	CDK8 is a colorectal cancer oncogene that regulates β -catenin activity. <i>Nature</i> , 2008, 455, 547-551.	13.7	594
128	Potential role of miR-9 and miR-223 in recurrent ovarian cancer. <i>Molecular Cancer</i> , 2008, 7, 35.	7.9	269
129	p16INK4A genetic and epigenetic profiles differ in relation to age and site in head and neck squamous cell carcinomas. <i>Human Pathology</i> , 2008, 39, 452-458.	1.1	69
130	BRAF T1799A Mutation Occurring in a Case of Malignant Struma Ovarii. <i>International Journal of Surgical Pathology</i> , 2007, 15, 116-120.	0.4	31
131	Prostate cancer: Re-focusing on androgen receptor signaling. <i>International Journal of Biochemistry and Cell Biology</i> , 2007, 39, 1562-1568.	1.2	37
132	Semiautomated Multiplexed Quantum Dot-Based in Situ Hybridization and Spectral Deconvolution. <i>Journal of Molecular Diagnostics</i> , 2007, 9, 20-29.	1.2	42
133	Surgical Feasibility Study of a Novel Polytetrafluoroethylene Graft Design for the Treatment of Peripheral Arterial Disease. <i>Annals of Vascular Surgery</i> , 2007, 21, 611-617.	0.4	12
134	A molecular expression signature distinguishing follicular lesions in thyroid carcinoma using preamplification RT-PCR in archival samples. <i>Modern Pathology</i> , 2007, 20, 1095-1102.	2.9	34
135	Identification of the JNK Signaling Pathway as a Functional Target of the Tumor Suppressor PTEN. <i>Cancer Cell</i> , 2007, 11, 555-569.	7.7	214
136	Expression microarray analysis of papillary thyroid carcinoma and benign thyroid tissue: emphasis on the follicular variant and potential markers of malignancy. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2007, 450, 249-260.	1.4	41
137	Low-Level Genomic Instability Is a Feature of Papillary Thyroid Carcinoma: An Array Comparative Genomic Hybridization Study of Laser Capture Microdissected Papillary Thyroid Carcinoma Tumors and Clonal Cell Lines. <i>Archives of Pathology and Laboratory Medicine</i> , 2007, 131, 65-73.	1.2	22
138	Effect of ret/PTC 1 rearrangement on transcription and post-transcriptional regulation in a papillary thyroid carcinoma model. <i>Molecular Cancer</i> , 2006, 5, 70.	7.9	59
139	Immunohistochemical evidence of Clostridium sp, Staphylococcus aureus, and group A Streptococcus in severe soft tissue infections related to injection drug use. <i>Human Pathology</i> , 2006, 37, 1482-1488.	1.1	23
140	Angioinvasive aspergillosis presenting as neutropenic colitis. <i>Histopathology</i> , 2006, 49, 440-441.	1.6	12
141	Distinct array comparative genomic hybridization profiles in oral squamous cell carcinoma occurring in young patients. <i>Head and Neck</i> , 2006, 28, 330-338.	0.9	35
142	The Isopeptidase USP2a Protects Human Prostate Cancer from Apoptosis. <i>Cancer Research</i> , 2006, 66, 8625-8632.	0.4	129
143	Cannonball metastases with favourable prognosis. <i>Irish Journal of Medical Science</i> , 2005, 174, 61-64.	0.8	6
144	ret/PTC and BRAF Act as Distinct Molecular, Time-Dependant Triggers in a Sporadic Irish Cohort of Papillary Thyroid Carcinoma. <i>International Journal of Surgical Pathology</i> , 2005, 13, 1-8.	0.4	43

#	ARTICLE	IF	CITATIONS
145	Array comparative genomic hybridisation analysis of gamma-irradiated human thyrocytes. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004, 445, 396-404.	1.4	14
146	Nucleic acid microarrays: an overview. <i>Current Diagnostic Pathology</i> , 2003, 9, 155-158.	0.4	8
147	Quality-control issues for PCR-based assays in the molecular laboratory. <i>Current Diagnostic Pathology</i> , 2003, 9, 165-172.	0.4	2
148	Ret/PTC Chimeric Transcripts in an Irish Cohort of Sporadic Papillary Thyroid Carcinoma. <i>Journal of Clinical Endocrinology and Metabolism</i> , 2003, 88, 938-941.	1.8	23
149	Real-Time Analysis of β - and β -Catenin mRNA Expression in ret/PTC-1 Activated and Nonactivated Thyroid Tissues. <i>Diagnostic Molecular Pathology</i> , 2003, 12, 44-49.	2.1	4
150	Non-metastatic primitive peripheral neuroectodermal tumour of the kidney (extraskeletal Ewing's) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 5	1.3	8
151	RET/PTC Rearrangements in Hashimoto's Thyroiditis. <i>International Journal of Surgical Pathology</i> , 2002, 10, 167-168.	0.4	16
152	The Node-Negative Neck: Accuracy of Clinical Intraoperative Lymph Node Assessment for Metastatic Disease in Head and Neck Cancer. <i>Laryngoscope</i> , 2002, 112, 630-633.	1.1	25
153	Real-time Quantitative Analysis of E-cadherin Expression in ret/PTC-1-Activated Thyroid Neoplasms. <i>International Journal of Surgical Pathology</i> , 2001, 9, 265-272.	0.4	17
154	Nodular fasciitis of the maxilla in a child. <i>Journal of Oral and Maxillofacial Surgery</i> , 2000, 58, 1447-1449.	0.5	16